How Engagements Begin

MolecPath is engaged when leadership teams face difficult-to-reverse decisions— 

where technical promise, regulatory reality, and market adoption must align under capital pressure. 

 MolecPath is typically engaged when organizations are navigating:

• Market entry, portfolio expansion, or repositioning
  where regulatory pathway, reimbursement, and adoption risk materially affect timing or valuation.
   
• Capital allocation and platform bets
  including build vs. partner vs. acquire decisions with board or investor visibility.
   
• Regulatory and adoption inflection points
  where classification, enforcement posture, or workflow friction introduce non-obvious risk.
   
• Commercialization risk in advanced diagnostics
  when strong science or technology fails to translate into sustainable market adoption.

Most MolecPath engagements begin with a Decision Access Engagement (DAE) — a short, paid advisory engagement designed to pressure-test a single high-consequence decision before capital, resources, or teams are committed.